Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.67 |
| ▸ | FYN | P06241 | 4/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | BCR | P11274 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895549 | 0.88 | SRC (0.71) | SRCABL1BCREGFR | |
| SCHEMBL3224282 | 0.87 | SRC (0.74) | SRCFYNABL1BCREGFR | |
| SCHEMBL3232019 | 0.87 | SRC (0.86) | SRCFYNABL1BCREGFR | |
| SCHEMBL3219474 | 0.84 | SRC (0.79) | SRCFYNABL1BCREGFR | |
| SCHEMBL3216675 | 0.84 | SRC (0.73) | SRCFYNABL1BCREGFR | |
| SCHEMBL3230553 | 0.84 | SRC (0.76) | SRCFYNABL1BCREGFR | |
| SCHEMBL3219402 | 0.84 | SRC (0.69) | SRCFYNABL1BCREGFR | |
| SCHEMBL3223524 | 0.84 | SRC (0.77) | SRCFYNABL1BCREGFR | |
| SCHEMBL3227888 | 0.84 | SRC (0.75) | SRCFYNABL1BCREGFR | |
| SCHEMBL3233747 | 0.83 | SRC (0.71) | SRCFYNABL1BCREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42376-E1 | Substituted 3-cyanoquinolines | WYETH HOLDINGS CORPORATION (US) | 2011-05-17 | — | — | US | claimed |
| EP-2253620-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2010-11-24 | — | — | EP | claimed |
| EP-1950201-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2008-07-30 | — | — | EP | claimed |
| US-6297258-B1 | USEFUL AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE. | AMERICAN CYANAMID COMPANY | 2001-10-02 | — | — | US | claimed |
| EP-1117649-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018740-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| EP-2896612-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2253620-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH HOLDINGS LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2253620-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009151910-A2 | COMBINATION PRODUCT OF RECEPTOR TYROSINE KINASE INHIBITOR AND FATTY ACID SYNTHASE INHIBITOR FOR TREATING CANCER | WYETH (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-1950201-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | FASN, FRS2, FGFR1 | SRC 9/4885FYN 33/4885ABL1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.